Patents by Inventor Robbert Boudewijns

Robbert Boudewijns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • LIVE-ATTENUATED FLAVIVIRUSES WITH HETEROLOGOUS ANTIGENS
    Publication number: 20230406889
    Abstract: The invention relates to polynucleotides comprising the sequence of a flavivirus preceded by a sequence encoding an N terminal part of a flavivirus Capsid protein, an immunogenic protein, or a part thereof comprising a an immunogenic peptide, and a 2A cleaving peptide, and to the virus encoded by such sequences. The invention further relates to the use of such polynucleotides and viruses as vaccines.
    Type: Application
    Filed: May 5, 2023
    Publication date: December 21, 2023
    Applicant: Katholieke Universiteit Leuven
    Inventors: Robbert Boudewijns, Kai Dallmeier, Johan Neyts
  • Live-attenuated flaviruses with heterologous antigens
    Patent number: 11680084
    Abstract: The invention relates to polynucleotides comprising the sequence of a flavivirus preceded by a sequence encoding an N terminal part of a flavivirus Capsid protein, an immunogenic protein, or a part thereof comprising a an immunogenic peptide, and a 2A cleaving peptide, and to the virus encoded by such sequences. The invention further relates to the use of such polynucleotides and viruses as vaccines.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: June 20, 2023
    Assignee: KATHOLIEKE UNIVERSITEIT LEUVEN
    Inventors: Robbert Boudewijns, Kai Dallmeier, Johan Neyts
  • LIVE-ATTENUATED FLAVIRUSES WITH HETEROLOGOUS ANTIGENS
    Publication number: 20200331969
    Abstract: The invention relates to polynucleotides comprising the sequence of a flavivirus preceded by a sequence encoding an N terminal part of a flavivirus Capsid protein, an immunogenic protein, or a part thereof comprising a an immunogenic peptide, and a 2A cleaving peptide, and to the virus encoded by such sequences. The invention further relates to the use of such polynucleotides and viruses as vaccines.
    Type: Application
    Filed: October 5, 2018
    Publication date: October 22, 2020
    Inventors: Robbert Boudewijns, Kai Dallmeier, Johan Neyts